12 research outputs found
Multicentric myxoid liposarcoma: report of two cases
<p>Abstract</p> <p>Background</p> <p>Multicentric myxoid liposarcoma is a rather infrequent tumour that tends to behave aggressively.</p> <p>Case presentation</p> <p>We herein report two further cases of this tumour that have been managed in our Hospital. Both were young men with multiple sites of involvement at the moment of diagnosis and both have shown a bad prognosis with frequent recurrences after treatment and rapid death in one case.</p> <p>Conclusion</p> <p>We comment on the diagnosis of this entity and on the therapeutic options available for these patients.</p
Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study
Background A phase I study found remarkable activity and manageable toxicity for doxorubicin (bolus) plus lurbinectedin (1-h intravenous [i.v.] infusion) on Day 1 every three weeks (q3wk) as second-line therapy in relapsed small cell lung cancer (SCLC). An expansion cohort further evaluated this combination. Patients and methods Twenty-eight patients with relapsed SCLC after no more than one line of cytotoxic-containing chemotherapy were treated: 18 (64%) with sensitive disease (chemotherapy-free interval [CTFI] ≥90 days) and ten (36%) with resistant disease (CTFI <90 days; including six with refractory disease [CTFI ≤30 days]). Results Ten patients showed confirmed response (overall response rate [ORR] = 36%); median progression-free survival (PFS) = 3.3 months; median overall survival (OS) = 7.9 months. ORR was 50% in sensitive disease (median PFS = 5.7 months; median OS = 11.5 months) and 10% in resistant disease (median PFS = 1.3 months; median OS = 4.6 months). The main toxicity was transient and reversible myelosuppression. Treatment-related non-hematological events (fatigue, nausea, decreased appetite, vomiting, alopecia) were mostly mild or moderate. Conclusion Doxorubicin 40 mg/m(2) and lurbinectedin 2.0 mg/m(2) on Day 1 q3wk has shown noteworthy activity in relapsed SCLC and a manageable safety profile. The combination is being evaluated as second-line therapy for SCLC in an ongoing, randomized phase III trial. Clinical trial registration www.ClinicalTrials.gov code: NCT01970540. Date of registration: 22 October, 2013
Evaluation of appendicitis risk prediction models in adults with suspected appendicitis
Background
Appendicitis is the most common general surgical emergency worldwide, but its diagnosis remains challenging. The aim of this study was to determine whether existing risk prediction models can reliably identify patients presenting to hospital in the UK with acute right iliac fossa (RIF) pain who are at low risk of appendicitis.
Methods
A systematic search was completed to identify all existing appendicitis risk prediction models. Models were validated using UK data from an international prospective cohort study that captured consecutive patients aged 16–45 years presenting to hospital with acute RIF in March to June 2017. The main outcome was best achievable model specificity (proportion of patients who did not have appendicitis correctly classified as low risk) whilst maintaining a failure rate below 5 per cent (proportion of patients identified as low risk who actually had appendicitis).
Results
Some 5345 patients across 154 UK hospitals were identified, of which two‐thirds (3613 of 5345, 67·6 per cent) were women. Women were more than twice as likely to undergo surgery with removal of a histologically normal appendix (272 of 964, 28·2 per cent) than men (120 of 993, 12·1 per cent) (relative risk 2·33, 95 per cent c.i. 1·92 to 2·84; P < 0·001). Of 15 validated risk prediction models, the Adult Appendicitis Score performed best (cut‐off score 8 or less, specificity 63·1 per cent, failure rate 3·7 per cent). The Appendicitis Inflammatory Response Score performed best for men (cut‐off score 2 or less, specificity 24·7 per cent, failure rate 2·4 per cent).
Conclusion
Women in the UK had a disproportionate risk of admission without surgical intervention and had high rates of normal appendicectomy. Risk prediction models to support shared decision‐making by identifying adults in the UK at low risk of appendicitis were identified
Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study
BACKGROUND: Lurbinectedin (PM01183) has synergistic antitumor activity when combined with doxorubicin in mice with xenografted tumors. This phase I trial determined the recommended dose (RD) of doxorubicin (bolus) and PM01183 (1-h intravenous infusion) on day 1 every 3 weeks (q3wk), and obtained preliminary evidence of antitumor activity for this combination in small-cell lung cancer (SCLC).
PATIENTS AND METHODS: Patients with advanced solid tumors received doxorubicin and PM01183 following a standard dose escalation design and expansion at the RD. Twenty-seven patients had relapsed SCLC: 12 with sensitive disease (platinum-free interval ≥90 days) and 15 with resistant disease (platinum-free interval <90 days).
RESULTS: Doxorubicin 50 mg/m2 and PM01183 4.0 mg flat dose was the RD. In relapsed SCLC, treatment tolerance at the RD was manageable. Transient and reversible myelosuppression (including neutropenia, thrombocytopenia, and febrile neutropenia) was the main toxicity, managed with dose adjustment and colony-stimulating factors. Fatigue (79%), nausea/vomiting (58%), decreased appetite (53%), mucositis (53%), alopecia (42%), diarrhea/constipation (42%), and asymptomatic creatinine (68%) and transaminase increases (alanine aminotransferase 42%; aspartate aminotransferase 32%) were common, and mostly mild or moderate. Complete (n = 2, 8%) and partial response (n = 13, 50%) occurred in relapsed SCLC, mostly at the RD. Response rates at second line were 91.7% in sensitive disease [median progression-free survival (PFS)=5.8 months] and 33.3% in resistant disease (median PFS = 3.5 months). At third line, response rate was 20.0% (median PFS = 1.2 months), all in resistant disease.
CONCLUSION: Doxorubicin 50 mg/m2 and PM01183 4.0 mg flat dose on day 1 q3wk has shown remarkable activity, mainly in second line, with manageable tolerance in relapsed SCLC, leading to further evaluation of this combination within an ongoing phase III trial
Ecological corridors in Costa Rica: An evaluation applying landscape structure, fragmentation-connectivity process, and climate adaptation
In recent years, ecological corridors have been proposed on a global scale as a response to the accelerated process of natural ecosystem fragmentation, mainly as a result of human impact. In accordance with this trend, Costa Rica has undergone a process of implementing ecological corridors as to promote ecological connectivity since the 1990s, with the establishment of 44 ecological corridors covering 38% of Costa Rica's territory. Nevertheless, there is no research evaluating these corridors on a national scale that takes into account their functions as conduits, barriers, and habitats. Thus, the objective of this research was to describe the process of biological corridor formation in Costa Rica, and to evaluate the potential effectiveness of corridors by considering aspects of landscape structure and ecological processes related to connectivity and fragmentation. We used the National Program of Ecological Corridors database along with coverage analysis from Landsat images from 2000 and 2015.The composition of the biological corridors was determined at the landscape scale and related to potential to maintain a specific population of wild mammals weighing more than 10 kg. The composition of the ecological corridors was highly variable in terms of total area, proportion of natural habitat, and fragmentation process. Most biological corridors are capable of maintaining viable populations of Pecari tajacu and Tapir bairdii, while none could maintain populations of Panthera onca and Tayassu pecari. Only 50% of the biological corridors had improved in their connectivity. Therefore, public policies, such as master plans focusing on ecosystem restoration must be established. In addition, only two biological corridors incorporate the majority of elevation ranges (Life Zones) present in the country, which reduces the potential of the corridor system as a tool for climate change adaptation.En los últimos años se han propuesto corredores ecológicos a escala global como respuesta al proceso acelerado de fragmentación de los ecosistemas naturales, principalmente como consecuencia del impacto humano. De acuerdo con esta tendencia, Costa Rica ha experimentado un proceso de implementación de corredores ecológicos para promover la conectividad ecológica desde la década de 1990, con el establecimiento de 44 corredores ecológicos que cubren el 38% del territorio costarricense. Sin embargo, no existe una investigación que evalúe estos corredores a escala nacional que tenga en cuenta sus funciones como conductos, barreras y hábitats. Por lo tanto, el objetivo de esta investigación fue describir el proceso de formación del corredor biológico en Costa Rica y evaluar la efectividad potencial de los corredores considerando aspectos de la estructura del paisaje y los procesos ecológicos relacionados con la conectividad y la fragmentación. Utilizamos la base de datos del Programa Nacional de Corredores Ecológicos junto con análisis de cobertura de imágenes Landsat de 2000 y 2015. La composición de los corredores biológicos se determinó a escala de paisaje y se relacionó con el potencial para mantener una población específica de mamíferos silvestres que pesa más de 10 kg . La composición de los corredores ecológicos fue muy variable en términos de área total, proporción de hábitat natural y proceso de fragmentación. La mayoría de los corredores biológicos son capaces de mantener poblaciones viables de Pecari tajacu y Tapir bairdii, mientras que ninguno pudo mantener poblaciones de Panthera onca y Tayassu pecari. Solo el 50% de los corredores biológicos habían mejorado en su conectividad. Por lo tanto, se deben establecer políticas públicas, como planes maestros enfocados en la restauración de ecosistemas. Además, solo dos corredores biológicos incorporan la mayoría de rangos de elevación (Zonas de Vida) presentes en el país, lo que reduce el potencial del sistema de corredores como herramienta de adaptación al cambio climático.Universidad Nacional, Costa RicaEscuela de Ciencias GeográficasInstituto Internacional en Conservación y Manejo de Vida Silvestr
Ecological corridors in Costa Rica: An evaluation applying landscape structure, fragmentation‐connectivity process, and climate adaptation
Stop Hypertension with SLP/UCM I
El Proyecto Stop Hipertensión con ApS/UCM pretende aportar nuestro granito de arena a la lucha contra la hipertensión arterial (HTA), utilizando una herramienta educativa de aprendizaje en servicio (ApS), que permita a los estudiantes de los Grados en ciencias de la salud de la UCM aprender a la vez que realizan un servicio público.
La hipertensión arterial (HTA) es un problema de salud pública y un importante factor de riesgo de padecer enfermedades cardiovasculares (ECV). Su diagnóstico está determinado por la medida de la presión arterial (PA) por lo que es de extrema importancia asegurar una medida fiable y válida. La automedida de la PA (AMPA) consiste en la medida de la PA por el propio paciente o un familiar, habitualmente en su domicilio, y es una herramienta útil para el diagnóstico y control de la HTA. Pero ¿sabemos medirnos de forma correcta la PA? ¿Usamos bien los tensiómetros? ¿Sabemos interpretar los registros de la PA y cuándo consultar al médico? Realizar AMPA correctamente no es fácil y exige un esfuerzo extraordinario de recursos humanos y económicos por parte de los profesionales de Atención Primaria. Por ello son necesarias nuevas estrategias para capacitar a la población en AMPA.
Con este Proyecto nos proponemos luchar contra la HTA a través de la metodología educativa de aprendizaje-servicio que combina objetivos académicos con el servicio comunitario. El alumnado de los grados de Ciencias de la Salud de la UCM forman a la población en la correcta AMPA, asesorándoles sobre el uso correcto de los tensiómetros, enseñándoles a interpretar los resultados y alertándoles de cuándo acudir al médico. En el curso 2022-2023, el servicio público se ha dirigido principalmente al colectivo de mayores por ser especialmente vulnerables a padecer ECV en los Ayuntamientos de Coslada, Alcobendas y Alcorcón, y en las residencias Afanias y Neurovida, y a la población general que acuda a la Facultad durante la Semana de la Ciencia CAM/UCM 2022, a la Feria de la Salud de Coslada y a la campaña contra la HTA de la UCM junto con el Servicio de Medicina del Trabajo. Hemos demostrado que este proyecto es una herramienta rentable y efectiva en la lucha contra la HTA, vinculando la salud pública, los recursos de los ayuntamientos y la universidad. Se cubre así una necesidad y servicio social que podría salvar muchas vidas con recursos de bajo costo, cumpliendo con los objetivos del desarrollo sostenible y con los objetivos de la Sociedad Española de Hipertensión (SEH-LELHA) y de la estrategia HEARTS de la OPS/OMS. Los estudiantes se dan cuenta de la realidad de la Salud pública al tener contacto directo con la población, realizando un servicio a la sociedad, y desarrollándose profesionalmente.
Agrademos su colaboración a:
Los ayuntamientos de Coslada, Alcorcón y Alcobendas de Madrid.
Las residencias de mayores Afanias y Neurovida.
Las Sociedades científicas SEH-LELHA, SECF y SEAPEC.
El Dr. Orduñez, lider de la estrategia HEARTS PAHO/WHO
Los colegios profesionales COFM y CODEM.
Las empresas River International S.L. (Beurer) and Peroxfarma S.L. (Omrom)Oficina APS UCMDepto. de FisiologíaFac. de FarmaciaTRUEunpu